Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.0% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,527,101 shares of the medical equipment provider’s stock after selling 15,524 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Hologic were worth $124,398,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of HOLX. Trustmark National Bank Trust Department purchased a new position in shares of Hologic in the 3rd quarter valued at about $213,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Hologic by 8.6% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock worth $200,952,000 after buying an additional 195,285 shares during the period. Pzena Investment Management LLC purchased a new position in Hologic in the third quarter valued at about $247,000. First Horizon Advisors Inc. lifted its position in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Hologic during the 3rd quarter worth approximately $2,350,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on HOLX shares. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and cut their price target for the stock from $95.00 to $85.00 in a research note on Tuesday, October 1st. Mizuho lowered their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. JPMorgan Chase & Co. lifted their target price on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Finally, Stephens reaffirmed an “overweight” rating and issued a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $89.91.

Hologic Stock Up 1.0 %

HOLX stock opened at $79.73 on Tuesday. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67. The stock has a market capitalization of $18.52 billion, a P/E ratio of 23.94, a PEG ratio of 2.49 and a beta of 0.98. The company has a 50 day moving average price of $80.38 and a two-hundred day moving average price of $78.38. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same period in the prior year, the firm posted $0.89 earnings per share. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. As a group, sell-side analysts expect that Hologic, Inc. will post 4.27 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.